收藏切换
Observation on efficacy, pharmacokinetic behaviors and safety of new modified RNA oligonucleotide targeting Foxo-1 via two routes of administration
收藏切换
PDF
Zhuo YANG1, *, Wen QIN1, Jing-bo WANG1, Li-yuan WANG1, Qin ZHUO1, Bo TIAN2
Acta Pharmaceutica Sinica | 2019, 54(7) : 1251 - 1256
Less
收藏切换
Acta Pharmaceutica Sinica | 2019, 54(7): 1251-1256
Original Articles
Observation on efficacy, pharmacokinetic behaviors and safety of new modified RNA oligonucleotide targeting Foxo-1 via two routes of administration
Full
Zhuo YANG1, *, Wen QIN1, Jing-bo WANG1, Li-yuan WANG1, Qin ZHUO1, Bo TIAN2
Affiliations
  • 1. Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
  • 2. Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
Published: 2019-07-12 doi: 10.16438/j.0513-4870.2019-0169
Outline
收藏切换

Foxo-1 plays an important role in development of muscle atrophy, serving as a potential target for therapeutic treatment of the disease. In this study, the Foxo-1 mRNA was targeted by a Foxo-1 specific RNA oligonucleotide modified by 2'-O-methyl and with a butanol tag at the 3'-end. To understand the in vivo significance of new modified RNA oligos, efficacy, pharmacokinetic and safety profiles of the new modified RNA oligonucleotide targeting Foxo-1 were evaluated in mice. All experimental protocols were approved by the Animal Ethics Committee of Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention. The results showed that different doses of the RNA oligonucleotide can reduce the expression of Foxo-1 in mice by two routes of administration, leading to an increase in skeletal muscle mass of the mice. The results of pharmacokinetic evaluation showed that the plasma disappearance curve for the RNA oligonucleotide could be described by a two-compartmental model. The results of safety evaluation showed that no obvious adverse effects on renal and hepatic functions, nor on hematological parameters by intravenous or oral administration of the RNA oligo with a maximum dose of 30 mg·kg-1. Histopathology also did not reveal any significant changes in the morphology of the organs studied. In conclusion, the new modified RNA oligo is safe and effective in mice, providing experimental evidence supporting the significance for its clinical application.

Foxo-1  /  antisense oligonucleotides  /  efficacy  /  pharmacokinetic behavior  /  safety
Zhuo YANG, Wen QIN, Jing-bo WANG, Li-yuan WANG, Qin ZHUO, Bo TIAN. Observation on efficacy, pharmacokinetic behaviors and safety of new modified RNA oligonucleotide targeting Foxo-1 via two routes of administration[J]. Acta Pharmaceutica Sinica, 2019 , 54 (7) : 1251 -1256 . DOI: 10.16438/j.0513-4870.2019-0169
Year 2019 volume 54 Issue 7
PDF
150
67
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2019-0169
  • Receive Date:2019-03-11
  • Online Date:2026-01-26
  • Published:2019-07-12
Article Data
Affiliations
History
  • Received:2019-03-11
  • Revised:2019-04-25
Affiliations
    1. Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
    2. Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2019-0169
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT